source
- Pediatric rare cancer research draws steady investment despite biotech market volatilityThe article notes that pediatric rare cancers continue to attract investment because they address the greatest unmet medical needs and allow clear measurement of patient impact. Even as the biotec…
- Opinion: Capricor’s Duchenne muscular dystrophy drug and the countless tiny decisions that can make or break a study“Regulatory flexibility can be exercised in rare disease without sacrificing rigor,” writes Mindy Leffler, whose son has Duchenne muscular dystrophy.STAT · 39m ago↗ source
- STAT+: How health systems are embracing chatbots to query and summarize patient records